Key result
Robotic-assisted radical prostatectomy is being performed on increasingly frail patients (P<0.001) without an increase in perioperative mortality or major morbidity (P>0.264).
Why the study?
Robotic-assisted radical prostatectomy is increasingly used in frailer populations, but trends in population frailty and postoperative morbidity and mortality needed illustration.
Does the increasing frailty of patients undergoing robotic-assisted radical prostatectomy affect postoperative morbidity and mortality?
Observational (n=66,683)
Yes
Does the increasing frailty of patients undergoing robotic-assisted radical prostatectomy affect postoperative morbidity and mortality?
Robotic-assisted radical prostatectomy is increasingly performed on frailer patients without an associated increase in perioperative morbidity or mortality.
Background: Robotic-assisted radical prostatectomy (RARP) has been found to be comparable and, in some cases, favorable to open surgical approaches, while being used in a frailer population. Objectives: We aimed to illustrate the trend in population frailty and compare morbidity and mortality postoperatively in patients who underwent RARP. Design and Methods: The National Surgical Quality Improvement Program data set was used to select patients who underwent RARP between the years 2011–2019. Age, frailty indicators, surgical characteristics, and perioperative morbidity and mortality were compared between the years 2011–2019 using the chi-square test (χ 2 ) for categorical variables and the one-way analysis of variance (ANOVA) for continuous variables. Results: Our patient population consisted of 66,683 patients who underwent RARP. There was an increase in mean age and frailty indicated by an increase in 5-item frailty score ⩾2, metabolic syndrome index = 3, and American Society of Anesthesiologists’ (ASA) class ⩾3 between the years 2011–2019 ( p < 0.001). Whereas the rate of mortality and morbidity, indicated by postoperative Clavien–Dindo grade ⩾4 and major morbidity, remained the same over the same period ( p > 0.264). Furthermore, operative time and length of stay decreased over the same period ( p < 0.001). Conclusion: RARP is being performed on more frail patients, with no added morbidity or mortality.
No takes yet. Share an insight, caveat, or question.
Heidar et al. (2023) conducted an observational in Prostate cancer (n=66,683). Robotic-assisted radical prostatectomy (RARP) vs. Earlier years (trend from 2011 to 2019) was evaluated on Postoperative Clavien-Dindo grade ⩾4 and major morbidity (p=>0.264). Robotic-assisted radical prostatectomy is being performed on increasingly frail patients (P<0.001) without an increase in perioperative mortality or major morbidity (P>0.264).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: